Personen

Dr. Tagrid Leménager

Tel.: 0621 1703-3907

Fax: 0621 1703-3505

E-Mail

Suchttagesklinik, 2. OG, Raum 203

Publikationen

Publikationen in peer-reviewed Zeitschriften seit 2006

TOP 5 Publikationen:

  1. Mann K, Roos CR, Hoffmann S, Nakovics H, Leménager T, Heinz A, Witkiewitz K. Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response among Reward and Relief Drinking Phenotypes. Neuropsychopharmacology. 2018 43(4):891-899. Epub 2017 Nov 20.
  2. Mann K, Leménager T, Hoffmann S, Reinhard I, Hermann D, Batra A, Berner M, Wodarz N, Heinz A, Smolka MN, Zimmermann US, Wellek S, Kiefer F, Anton RF, The PREDICT Study Team . Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol. 2013 18(6):937-46. Epub 2012 Dec 12.
  3. Puls I, Mohr J, Wrase J, Vollstädt-Klein S, Leménager T, Vollmert C, Rapp M, Obermayer K, Heinz A, Smolka MN. A model comparison of COMT effects on central processing of affective stimuli. Neuroimage. 2009 46(3):683-91.
  4. Zois E, Kiefer F, Leménager T, Vollstädt-Klein S, Mann K, Fauth-Bühler M. Frontal cortex gray matter volume alterations in pathological gambling occur independently from substance use disorder. Addict Biol. 2017 22(3):864-872. Epub 2016 Jan 15.
  5. Kiefer F, Witt SH, Frank J, Richter A, Treutlein J, Leménager T, Nöthen MM, Cichon S, Batra A, Berner M, Wodarz N, Zimmermann US, Spanagel R, Wiedemann K, Smolka MN, Heinz A, Rietschel M, Mann K. Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. Pharmacogenomics J. 2011 11(5):368-74.